Decera Clinical Education APP Podcast

Management of Atopic Dermatitis in Primary Care and Specialty Settings

Episode Summary

In this podcast episode, leading dermatology experts, Dr Jonathan Silverberg and Ms Victoria Garcia-Albea discuss their experiences with novel agents and their place in therapy for moderate to severe atopic dermatitis (AD).

Episode Notes

This podcast episode is part of a multimedia program discussing the co-management of moderate to severe atopic dermatitis (AD) in the primary care and specialty settings. Tune in to hear Dr Silverberg and NP Victoria Garcia-Albea highlight newly approved agents and the recent expanded labeling of an existing AD therapy, including: 

• Ruxolitinib, a topical JAK inhibitor for mild to moderate AD approved in 2021 
• Abrocitinib and upadacitinib, oral JAK inhibitors approved in early 2022 for moderate to severe AD
• Tralokinumab, an IL-13 inhibitor available as a subcutaneous injection, which was approved in late 2021 for moderate to severe AD
• Expanded approval for use in patients as young as 6 months for dupilumab, a subcutaneous IL-4 receptor α inhibitor

Presenters: 

Jonathan Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN
Director
Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

To view other program offerings, including a CE-certified recorded roundtable webcast, a ClinicalThought commentary, and to download slides, visit:
https://bit.ly/3PiupXZ